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cytotoxic T cells) returned to normal levels.2 In 
the two patients described by Clatworthy et al., 
the number of CD8+ T lymphocytes was low (190 
and 80 cells per cubic millimeter; normal range, 
200 to 900), but the number of CD19+ cells was 
within the normal range. Since alemtuzumab could 
eliminate about 77% of CD8+ T lymphocytes by 
means of non–complement-mediated mech an isms,3 
persistently suppressed CD8+ T cells could have 
influenced the development of anti–glomerular 
basement membrane antibodies in their patients.
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The Authors Reply: Shin and Lee suggest that 
the development of anti–glomerular basement 
membrane disease in two patients treated with 
alemtuzumab was due to a deficiency of CD8 sup-
pressor T cells. The speculation is based on a de-
scription of a patient with atypical, spontaneously 
resolving, anti–glomerular basement membrane 
disease in which low levels of so-called CD8 sup-
pressor T cells were observed.1 The OKT8 antibody 
that was used to define suppressors in this article 
merely identifies CD8 T cells, with no demonstra-
tion of a deficiency of suppressor function within 
this subgroup. Aside from the limitations of this 
article, CD8 T-cell depletion actually prevents or 
ameliorates disease in animal models of anti–glom-
erular basement membrane disease.2 In addition, 
data suggest that CD8 regulatory T cells in humans 
reside in the CD8+CD28− T-cell compartment.3 
After treatment with alemtuzumab, this regulator-
containing CD8+CD28− subgroup is enriched 
within the reconstituted CD8 T-cell compartment.4
Since acceptance of our letter, we have become 
aware that one of our two patients was previously 
mentioned in the adverse-effects section of an 
article on alemtuzumab in multiple sclerosis.5
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Osteosarcoma Derived from Donor Stem Cells Carrying  
the Norrie’s Disease Gene 
To the Editor: There have been few reports of 
osteosarcoma after allogeneic bone marrow trans-
plantation.1 We report the development of osteo-
sarcoma in a recipient 17 years after stem-cell 
transplantation. 
A 23-month-old boy with β-thalassemia re-
ceived a bone marrow transplant from his HLA-
identical 11-year-old brother in September 1989. 
Norrie’s disease had been diagnosed in the do-
nor at 12 months of age, after enucleation of the 
right eye was performed because a bilateral reti-
noblastoma was suspected. No genetic analysis 
was conducted at the time of surgery. Norrie’s 
disease is an X-linked recessive disease caused by 
mutations in the NDP gene on Xp11.4.2 It primar-
ily affects the eye and almost always leads to blind-
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ness. The chemotherapy regimen before the bone 
marrow transplantation consisted of high-dose 
cyclophosphamide and busulfan. From day 30, the 
recipient was a complete hematopoietic chimera. 
Seventeen years later, a metastatic chondroblastic 
osteosarcoma of the pelvis developed in the 
18-year-old recipient. Despite aggressive treat-
ment, the patient died of tumor progression 22 
months after the diagnosis of osteosarcoma and 
19 years after stem-cell transplantation. 
An osteosarcoma cell line that was established 
from the recipient’s tumor had a doubling time of 
168 hours (7 days) (the normal doubling time in 
a generated osteosarcoma cell line is 1.4 to 37.0 
days). The cells expressed mesenchymal stem-cell 
markers (CD44, CD29, CD105, CD90, and CD73) 
at a very high level (Fig. 1), but they did not ex-
press CD45, CD14, CD34, CD49, or CD24. Cells 
from the osteosarcoma cell line were examined 
by means of cytogenetic analysis and fluorescence 
in situ hybridization (FISH) with the use of a 
specific probe for the p53 gene.3 Fifty metaphases 
were analyzed after GTG banding. Two distinct 
karyotypes were found: 47XY,−5,+22,+m and 
45XY,−12,−15,+m. Blood samples from the recip-
ient and donor had wild-type copies of chromo-
some 17, whereas the osteosarcoma cell line 
showed trisomy 17 in 22 of 100 interphase nuclei. 
Neither the cytogenetic analysis nor p53 FISH 
analysis of the primary tumor was performed be-
cause of an inadequate specimen, and for ethical 
reasons, donor mesenchymal stem cells were not 
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Figure 1. Osteosarcoma Cell-Line Immunophenotype and Chimerism.
Panel A shows the results of flow-cytometric analysis and the osteosarcoma cell-line immunophenotype. A total of 2×105 to 5×105 cells 
were stained for 20 minutes with monoclonal antibodies against CD45, CD14, CD34, CD49, CD24, CD44, CD29, CD105, CD90, and CD73 
(Beckman Coulter) and 0.5 mg of propidium iodide per milliliter (Sigma) for the viability analysis. Appropriate combinations of fluores-
cein isothiocyanate–conjugated, phycoerythrin-conjugated, and peridinin chlorophyll protein–conjugated monoclonal antibodies were 
used. Labeled cells were analyzed on an Epics XL cytometer (Beckman Coulter) with the use of the XL2 software program. Gray denotes 
negative controls, and green denotes positive cells. The horizontal lines indicate the percentages of positive cells in the samples. Panel B 
shows chimerism. Genomic DNA was extracted from the patient’s peripheral blood, pelvic-biopsy specimen, and osteosarcoma cell line 
and from the donor’s peripheral blood with the use of standard procedures (the phenol–chloroform method). To evaluate chimerism, a 
semiquantitative approach based on polymerase-chain-reaction amplification of polymorphic genes (DNA variation sequences with a 
frequency of more than 1% in humans, such as variable numbers of tandem repeats) was used. The primers were 5′GCCCCATAGGTTTT-
GAACTCA3′ (forward primer) and 5′TGATTTGTCTGTAATTGCCAGC3′ (reverse primer).
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analyzed at the time of the diagnosis of osteo-
sarcoma. A semiquantitative method based on 
polymerase-chain-reaction amplification of poly-
morphic genes showed complete donor chimerism 
of recipient hematopoietic cells, the cells from the 
osteosarcoma-biopsy specimen, and the osteosar-
coma cell line (Fig. 1).3 Moreover, the blood sam-
ples from the donor and the recipient, the osteo-
sarcoma-biopsy specimen, and the osteosarcoma 
cell line had a mutation of L15R of exon 2 of the 
NDP gene, whereas swab cells from the recipient’s 
oral cavity did not. 
Our data suggest the donor origin of the osteo-
sarcoma. The mutated NDP in the osteosarcoma 
cells was most likely a marker of chimerism, be-
cause cancer did not develop in the donor, and 
Norrie’s disease is not associated with an increased 
risk of cancer.
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